Introduction of a second MenB vaccine into Europe – needs and opportunities for public health

Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination

(2018) Alexandra Thabuis et al.   Eurosurveillance

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine

(2018) John L. Perez et al.   Expert Review of Vaccines

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

(2018) Lisa K. McNeil et al.   mBio

Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults

(2018) Xavier Sáez-Llorens et al.   Human Vaccines & Immunotherapeutics

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

(2018) Paul Balmer et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study

(2018) Wilbur H Chen et al.   LANCET INFECTIOUS DISEASES

Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function

(2018) Federico Martinón-Torres et al.   PEDIATRICS

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci

(2018) Shannon L. Harris et al.   VACCINE

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial

(2017) Helen S Marshall et al.   LANCET INFECTIOUS DISEASES

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

(2017) Lars Ostergaard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains

(2017) Shannon L. Harris et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014

(2017) Robert Whittaker et al.   VACCINE

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016

(2017) Monica E. Patton et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Can we control all-cause meningococcal disease in Europe?

(2016) M. Sadarangani et al.   CLINICAL MICROBIOLOGY AND INFECTION

Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations

(2016) Carol J. Baker   JOURNAL OF ADOLESCENT HEALTH

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

(2016) Nicole E. Basta et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents

(2016) Derek Muse et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine

(2016) Shelly Senders et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serogroup and Clonal Characterization of Czech Invasive Neisseria meningitidis Strains Isolated from 1971 to 2015

(2016) Zuzana Jandova et al.   PLoS One

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)

(2016) Ashesh Gandhi et al.   POSTGRADUATE MEDICINE

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults

(2016) Lars Ostergaard et al.   VACCINE

Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers

(2016) David M. Reiner et al.   VACCINE

High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland

(2016) Izabela Waśko et al.   VACCINE

Meningococcal serogroup B vaccines: Estimating breadth of coverage

(2016) Robert G. K. Donald et al.   Human Vaccines & Immunotherapeutics

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents

(2016) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy

(2015) Catherine A. Jeppesen et al.   JOURNAL OF INFECTION

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents

(2015) Xavier Saez-Llorens et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

(2015) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine

(2014) Georgina Tzanakaki et al.   BMC MICROBIOLOGY

Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales

(2014) Shamez N. Ladhani et al.   CLINICAL INFECTIOUS DISEASES

Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013

(2014) C Chatt et al.   Eurosurveillance

Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years

(2014) R. Gasparini et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis

(2014) Ludovic Lemée et al.   PLoS One

A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants

(2014) Federico Martinon-Torres et al.   VACCINE

Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway

(2014) Johan Holst et al.   VACCINE

The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease

(2014) Gary W Zlotnick et al.   Human Vaccines & Immunotherapeutics

Comparison of posterior pharyngeal wall and nasopharyngeal swabbing as a means of detecting the carriage of Neisseria meningitidis in adolescents

(2013) S. Esposito et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

(2013) L. K. McNeil et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups

(2013) Susan K. Hoiseth et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands

(2013) Stefania Bambini et al.   PLoS One

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future

(2013) Johan Holst et al.   Human Vaccines & Immunotherapeutics

A cluster of four cases of meningococcal disease in a single nuclear family

(2012) P Acheson et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

Functional impacts of the diversity of the meningococcal factor H binding protein

(2012) Eva Hong et al.   VACCINE

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

(2012) Eric Sheldon et al.   Human Vaccines & Immunotherapeutics

Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century

(2011) Paula Kriz et al.   Expert Review of Vaccines

Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease

(2011) Shannon L. Harris et al.   Human vaccines & immunotherapeutics

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE

Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine

(2010) J. Lucidarme et al.   Clinical and Vaccine Immunology

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales

(2009) J. Lucidarme et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

(2009) Lisa K. McNeil et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37

(2008) K. L. Seib et al.   INFECTION AND IMMUNITY

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES